Massachusetts Financial Services Co. MA increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 688,228 shares of the biopharmaceutical company’s stock after acquiring an additional 15,831 shares […]
Swiss National Bank lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 10.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 400,600 shares of the biopharmaceutical company’s stock after selling 47,000 shares during the quarter. Swiss National Bank’s holdings […]
Clearstead Advisors LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 197.6% during the third quarter, HoldingsChannel.com reports. The fund owned 4,518 shares of the biopharmaceutical company’s stock after buying an additional 3,000 shares during the period. Clearstead Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $800,000 at the end of […]
Privium Fund Management B.V. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 20,023 shares of the biopharmaceutical company’s stock, valued at approximately $3,546,000. Alnylam Pharmaceuticals accounts for about 1.1% of Privium Fund Management B.V.’s holdings, making the stock its […]
Nomura Asset Management Co. Ltd. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 68,017 shares of the biopharmaceutical company’s stock after purchasing an additional 1,804 shares during the quarter. […]